Navigation Links
$4.7 million study looks at why diabetes makes heart disease worse
Date:7/12/2012

Researchers at Washington University School of Medicine in St. Louis have received a $4.7 million grant from the National Heart, Lung, and Blood Institute to investigate heart disease in patients with diabetes.

"Diabetes is an incredibly common problem," says Jean E. Schaffer, MD, the Virginia Minnich Distinguished Professor of Medicine. "It affects a huge swath of the population. Importantly, people with diabetes don't just have a metabolic disorder. They develop complications in many organs. And one of the most deadly complications is heart disease. We're particularly interested in why people with diabetes suffer from unusually severe forms of heart disease."

For reasons not fully understood, people with diabetes are more likely to develop blockages in arteries. After a heart attack, the course of the subsequent heart disease is more aggressive than in people without diabetes. And even independent of blocked arteries, there is evidence that their hearts do not function like those of individuals without diabetes.

According to the Centers for Disease Control and Prevention, almost 26 million Americans are living with type 2 diabetes and another 79 million with undiagnosed diabetes or pre-diabetes, a condition that increases their risk of developing the full-blown variety. With such statistics, it is becoming increasingly important to explore the reasons behind the aggressive progress of cardiovascular disease in patients whose bodies do not properly regulate blood sugar.

Schaffer and her colleagues suspect a likely culprit is abnormal lipid metabolism. Lipids are a class of molecules that include fats, such as fatty acids and triglycerides. Past studies have shown that patients with diabetes store higher levels of these lipids in their heart muscle, likely impairing cardiac function. These lipids appear to lead to inflammation and can also damage important parts of heart cells, such as proteins and DNA, leading to heart muscle dysfunction.

"The problem is that we haven't been able to make strong links between what we measure in a fasting blood sample, like triglycerides and free fatty acids, and the degree of heart muscle dysfunction," Schaffer says. "In this type of heart muscle disorder, these common blood tests are not a good predictor of who is at highest risk for heart disease."

The goal of the new research program is to identify better measures of heart disease in patients with diabetes. The program has four major parts:

Establish a clinically useful method to measure key lipids related to diabetes complications in blood samples.

Identify markers of abnormal lipid metabolism in existing blood samples from clinical trial participants, including those in the Framingham Heart Study. Such large, well-designed clinical trials often have collected both blood samples and non-invasive imaging studies of cardiovascular function such as echocardiograms. Comparing the two may show correlations between markers of abnormal lipid metabolism and heart function.

Design laboratory experiments, including studies in mouse models of diabetes and heart disease, to help understand how the abnormal lipids may contribute to heart muscle dysfunction.

Perform a clinical trial for patients with type 2 diabetes to examine whether a drug that lowers blood lipids improves heart function.

In addition to its own research program, Washington University will serve as the coordinating center among the five institutions chosen to receive funding from the National Institutes of Health (NIH) to study the abnormal metabolism of cardiovascular and lung diseases. The four partnering institutions are Cleveland Clinic, Emory University, National Jewish Health and Weill Cornell Medical College.

"We will be working with the NIH and our partner institutions to help researchers interact and inform new approaches and new ideas in other studies," Schaffer says.

Schaffer emphasizes the multidisciplinary and collaborative nature of the research program and credits the School of Medicine's BioMed 21 initiative for providing the resources to facilitate this type of translational project.


'/>"/>
Contact: Julia Evangelou Strait
straitj@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert

Related medicine news :

1. The Ben & Catherine Ivy Foundation contributes $10 million to TGen for brain cancer research
2. Gallo Research Center to lead $15 million US Army-funded national research program
3. $53 million grant will help health researchers develop new therapies -- with the publics help
4. Einstein receives nearly $5 million to study how Ebola causes infection
5. Recessions bite: Nearly 4 million Californians struggled to put food on table during downturn
6. TMC institutions get $20 million renewal grant for translational medicine center
7. Tufts Medical Center researchers receive $10 million NIH grant to test blood clot prevention drug
8. 5 Million Test Tube Babies Born to Date
9. Taxman Foundation pledges $2.5 million to boost training of digestive disease experts
10. Jaeckle Fleischmann Environmental Attorneys Recover Additional $5 Million for Solvent Chemical
11. 40 Million Americans Addicted to Cigarettes, Alcohol or Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement ... Vice President of North American Capital Sales at HTG Molecular . ... in the commercialization of the HTG EdgeSeq system and associated reagents in North America. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology: